Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment
Objective Radium-223 is a first alpha-emitting radionuclide treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with bone metastases. Although the spread-based bone scan index (BSI) and novel index of the intensity-based two-dimensional total bone uptake (2D-TBU) from bone...
Gespeichert in:
| Veröffentlicht in: | Annals of nuclear medicine 2024-06, Vol.38 (6), p.450-459 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 459 |
|---|---|
| container_issue | 6 |
| container_start_page | 450 |
| container_title | Annals of nuclear medicine |
| container_volume | 38 |
| creator | Fukai, Shohei Daisaki, Hiromitsu Umeda, Takuro Shimada, Naoki Terauchi, Takashi Koizumi, Mitsuru |
| description | Objective
Radium-223 is a first alpha-emitting radionuclide treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with bone metastases. Although the spread-based bone scan index (BSI) and novel index of the intensity-based two-dimensional total bone uptake (2D-TBU) from bone scintigraphy may provide useful input in radium-223 treatment, they have not been evaluated in detail yet. This study aimed to fill this gap by evaluating BSI and 2D-TBU in patients treated with radium-223.
Methods
Twenty-seven Japanese patients with mCRPC treated with radium-223 were retrospectively analyzed. The patients were evaluated via blood tests and bone scans at baseline and 3 cycles intervals of treatment. BSI and 2D-TBU were analyzed via VSBONE BSI in terms of correlations, response to radium-223 treatment, association with treatment completion, and the Kaplan–Meier survival analysis was performed.
Results
Nineteen patients (70.4%) completed six cycles of radium-223 treatment, whereas eight patients (29.6%) did not complete the treatment regimen. A significant difference in baseline BSI and 2D-TBU was observed between these groups of patients. Both BSI and 2D-TBU were highly correlated (r = 0.96,
p
|
| doi_str_mv | 10.1007/s12149-024-01918-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2974009010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3057773850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-4b6654ae93caf4df548211eabb8efc3deef6f87e04aa4f0e56540fb4043716d53</originalsourceid><addsrcrecordid>eNp9kbtuFTEQhi0EIofAC1AgSzQnhcG3vZUkJBApEgVJbXnX4xyHXXuxvbm8HM-Gk01AoqCxrZlv_t-aH6G3jH5glDYfE-NMdoRySSjrWEvkM7RhbS1JLYV4jja0Y5I0rG320KuUrijlbdXyl2hPtBVr6qrboF_H13pcdHbB42BxvgnEuAl8KgU94hxyOfvgAS9z1j8Ab_lncn54cYC1N2sjDdpj5w3c4u3h99MDDLc56iGDwTaGCZenu4aVnSDrlIvdgPslGiimHucdPCk5n91l1PPurijiuYDgc8I3Lu9w1MYtE-Fc4BxB5_LL_Bq9sHpM8Obx3kcXJ8fnR1_J2bcvp0efzsggeJ2J7Ou6kho6MWgrja1kyxkD3fct2EEYAFvbtgEqtZaWQlVoantJpWhYbSqxj7ar7hzDzwVSVpNLA4yj9hCWpHjXSEo7ymhB3_-DXoUllmUmJWjVNE1Z_j3FV2qIIaUIVs3RTTreKUbVfbpqTVeVdNVDukqWoXeP0ks_gfkz8hRnAcQKpNLylxD_ev9H9jdMd7Ho</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3057773850</pqid></control><display><type>article</type><title>Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment</title><source>Springer Nature - Complete Springer Journals</source><creator>Fukai, Shohei ; Daisaki, Hiromitsu ; Umeda, Takuro ; Shimada, Naoki ; Terauchi, Takashi ; Koizumi, Mitsuru</creator><creatorcontrib>Fukai, Shohei ; Daisaki, Hiromitsu ; Umeda, Takuro ; Shimada, Naoki ; Terauchi, Takashi ; Koizumi, Mitsuru</creatorcontrib><description>Objective
Radium-223 is a first alpha-emitting radionuclide treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with bone metastases. Although the spread-based bone scan index (BSI) and novel index of the intensity-based two-dimensional total bone uptake (2D-TBU) from bone scintigraphy may provide useful input in radium-223 treatment, they have not been evaluated in detail yet. This study aimed to fill this gap by evaluating BSI and 2D-TBU in patients treated with radium-223.
Methods
Twenty-seven Japanese patients with mCRPC treated with radium-223 were retrospectively analyzed. The patients were evaluated via blood tests and bone scans at baseline and 3 cycles intervals of treatment. BSI and 2D-TBU were analyzed via VSBONE BSI in terms of correlations, response to radium-223 treatment, association with treatment completion, and the Kaplan–Meier survival analysis was performed.
Results
Nineteen patients (70.4%) completed six cycles of radium-223 treatment, whereas eight patients (29.6%) did not complete the treatment regimen. A significant difference in baseline BSI and 2D-TBU was observed between these groups of patients. Both BSI and 2D-TBU were highly correlated (r = 0.96,
p
< 0.001). Univariate analysis showed an association between radium-223 completion in median BSI and 2D-TBU values (
p
= 0.015) and completion percentage differences (91.7% vs. 45.5%;
p
= 0.027). The Kaplan–Meier product limit estimator showed that the median overall survival was 25.2 months (95% CI 14.0–33.6 months) in the completion group and 7.5 months (95% CI 3.3–14.2 months) in the without completion group (
p
< 0.001). The overall survival based on median cutoff levels showed a significant difference in 2D-TBU (
p
= 0.007), but not in BSI (
p
= 0.15).
Conclusions
The 2D-TBU may offer advantages over BSI in classifying patients towards radium-223 treatment based on the degree of progression of bone metastases. This study supports the importance of preliminary assessment of bone metastasis status using BSI and 2D-TBU extracted from VSBONE BSI for radium-223 treatment decisions.</description><identifier>ISSN: 0914-7187</identifier><identifier>ISSN: 1864-6433</identifier><identifier>EISSN: 1864-6433</identifier><identifier>DOI: 10.1007/s12149-024-01918-4</identifier><identifier>PMID: 38517659</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Bone cancer ; Castration ; Evaluation ; Imaging ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Nuclear Medicine ; Original Article ; Prostate cancer ; Radioisotopes ; Radiology ; Radium ; Scintigraphy ; Survival ; Survival analysis ; Two dimensional analysis</subject><ispartof>Annals of nuclear medicine, 2024-06, Vol.38 (6), p.450-459</ispartof><rights>The Author(s), under exclusive licence to The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine 2024. corrected publication 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.</rights><rights>The Author(s), under exclusive licence to The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine 2024. corrected publication 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-4b6654ae93caf4df548211eabb8efc3deef6f87e04aa4f0e56540fb4043716d53</cites><orcidid>0000-0002-2321-2984</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12149-024-01918-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12149-024-01918-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38517659$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fukai, Shohei</creatorcontrib><creatorcontrib>Daisaki, Hiromitsu</creatorcontrib><creatorcontrib>Umeda, Takuro</creatorcontrib><creatorcontrib>Shimada, Naoki</creatorcontrib><creatorcontrib>Terauchi, Takashi</creatorcontrib><creatorcontrib>Koizumi, Mitsuru</creatorcontrib><title>Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment</title><title>Annals of nuclear medicine</title><addtitle>Ann Nucl Med</addtitle><addtitle>Ann Nucl Med</addtitle><description>Objective
Radium-223 is a first alpha-emitting radionuclide treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with bone metastases. Although the spread-based bone scan index (BSI) and novel index of the intensity-based two-dimensional total bone uptake (2D-TBU) from bone scintigraphy may provide useful input in radium-223 treatment, they have not been evaluated in detail yet. This study aimed to fill this gap by evaluating BSI and 2D-TBU in patients treated with radium-223.
Methods
Twenty-seven Japanese patients with mCRPC treated with radium-223 were retrospectively analyzed. The patients were evaluated via blood tests and bone scans at baseline and 3 cycles intervals of treatment. BSI and 2D-TBU were analyzed via VSBONE BSI in terms of correlations, response to radium-223 treatment, association with treatment completion, and the Kaplan–Meier survival analysis was performed.
Results
Nineteen patients (70.4%) completed six cycles of radium-223 treatment, whereas eight patients (29.6%) did not complete the treatment regimen. A significant difference in baseline BSI and 2D-TBU was observed between these groups of patients. Both BSI and 2D-TBU were highly correlated (r = 0.96,
p
< 0.001). Univariate analysis showed an association between radium-223 completion in median BSI and 2D-TBU values (
p
= 0.015) and completion percentage differences (91.7% vs. 45.5%;
p
= 0.027). The Kaplan–Meier product limit estimator showed that the median overall survival was 25.2 months (95% CI 14.0–33.6 months) in the completion group and 7.5 months (95% CI 3.3–14.2 months) in the without completion group (
p
< 0.001). The overall survival based on median cutoff levels showed a significant difference in 2D-TBU (
p
= 0.007), but not in BSI (
p
= 0.15).
Conclusions
The 2D-TBU may offer advantages over BSI in classifying patients towards radium-223 treatment based on the degree of progression of bone metastases. This study supports the importance of preliminary assessment of bone metastasis status using BSI and 2D-TBU extracted from VSBONE BSI for radium-223 treatment decisions.</description><subject>Bone cancer</subject><subject>Castration</subject><subject>Evaluation</subject><subject>Imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Nuclear Medicine</subject><subject>Original Article</subject><subject>Prostate cancer</subject><subject>Radioisotopes</subject><subject>Radiology</subject><subject>Radium</subject><subject>Scintigraphy</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Two dimensional analysis</subject><issn>0914-7187</issn><issn>1864-6433</issn><issn>1864-6433</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kbtuFTEQhi0EIofAC1AgSzQnhcG3vZUkJBApEgVJbXnX4xyHXXuxvbm8HM-Gk01AoqCxrZlv_t-aH6G3jH5glDYfE-NMdoRySSjrWEvkM7RhbS1JLYV4jja0Y5I0rG320KuUrijlbdXyl2hPtBVr6qrboF_H13pcdHbB42BxvgnEuAl8KgU94hxyOfvgAS9z1j8Ab_lncn54cYC1N2sjDdpj5w3c4u3h99MDDLc56iGDwTaGCZenu4aVnSDrlIvdgPslGiimHucdPCk5n91l1PPurijiuYDgc8I3Lu9w1MYtE-Fc4BxB5_LL_Bq9sHpM8Obx3kcXJ8fnR1_J2bcvp0efzsggeJ2J7Ou6kho6MWgrja1kyxkD3fct2EEYAFvbtgEqtZaWQlVoantJpWhYbSqxj7ar7hzDzwVSVpNLA4yj9hCWpHjXSEo7ymhB3_-DXoUllmUmJWjVNE1Z_j3FV2qIIaUIVs3RTTreKUbVfbpqTVeVdNVDukqWoXeP0ks_gfkz8hRnAcQKpNLylxD_ev9H9jdMd7Ho</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Fukai, Shohei</creator><creator>Daisaki, Hiromitsu</creator><creator>Umeda, Takuro</creator><creator>Shimada, Naoki</creator><creator>Terauchi, Takashi</creator><creator>Koizumi, Mitsuru</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2321-2984</orcidid></search><sort><creationdate>20240601</creationdate><title>Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment</title><author>Fukai, Shohei ; Daisaki, Hiromitsu ; Umeda, Takuro ; Shimada, Naoki ; Terauchi, Takashi ; Koizumi, Mitsuru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-4b6654ae93caf4df548211eabb8efc3deef6f87e04aa4f0e56540fb4043716d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Bone cancer</topic><topic>Castration</topic><topic>Evaluation</topic><topic>Imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Nuclear Medicine</topic><topic>Original Article</topic><topic>Prostate cancer</topic><topic>Radioisotopes</topic><topic>Radiology</topic><topic>Radium</topic><topic>Scintigraphy</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Two dimensional analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fukai, Shohei</creatorcontrib><creatorcontrib>Daisaki, Hiromitsu</creatorcontrib><creatorcontrib>Umeda, Takuro</creatorcontrib><creatorcontrib>Shimada, Naoki</creatorcontrib><creatorcontrib>Terauchi, Takashi</creatorcontrib><creatorcontrib>Koizumi, Mitsuru</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fukai, Shohei</au><au>Daisaki, Hiromitsu</au><au>Umeda, Takuro</au><au>Shimada, Naoki</au><au>Terauchi, Takashi</au><au>Koizumi, Mitsuru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment</atitle><jtitle>Annals of nuclear medicine</jtitle><stitle>Ann Nucl Med</stitle><addtitle>Ann Nucl Med</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>38</volume><issue>6</issue><spage>450</spage><epage>459</epage><pages>450-459</pages><issn>0914-7187</issn><issn>1864-6433</issn><eissn>1864-6433</eissn><abstract>Objective
Radium-223 is a first alpha-emitting radionuclide treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with bone metastases. Although the spread-based bone scan index (BSI) and novel index of the intensity-based two-dimensional total bone uptake (2D-TBU) from bone scintigraphy may provide useful input in radium-223 treatment, they have not been evaluated in detail yet. This study aimed to fill this gap by evaluating BSI and 2D-TBU in patients treated with radium-223.
Methods
Twenty-seven Japanese patients with mCRPC treated with radium-223 were retrospectively analyzed. The patients were evaluated via blood tests and bone scans at baseline and 3 cycles intervals of treatment. BSI and 2D-TBU were analyzed via VSBONE BSI in terms of correlations, response to radium-223 treatment, association with treatment completion, and the Kaplan–Meier survival analysis was performed.
Results
Nineteen patients (70.4%) completed six cycles of radium-223 treatment, whereas eight patients (29.6%) did not complete the treatment regimen. A significant difference in baseline BSI and 2D-TBU was observed between these groups of patients. Both BSI and 2D-TBU were highly correlated (r = 0.96,
p
< 0.001). Univariate analysis showed an association between radium-223 completion in median BSI and 2D-TBU values (
p
= 0.015) and completion percentage differences (91.7% vs. 45.5%;
p
= 0.027). The Kaplan–Meier product limit estimator showed that the median overall survival was 25.2 months (95% CI 14.0–33.6 months) in the completion group and 7.5 months (95% CI 3.3–14.2 months) in the without completion group (
p
< 0.001). The overall survival based on median cutoff levels showed a significant difference in 2D-TBU (
p
= 0.007), but not in BSI (
p
= 0.15).
Conclusions
The 2D-TBU may offer advantages over BSI in classifying patients towards radium-223 treatment based on the degree of progression of bone metastases. This study supports the importance of preliminary assessment of bone metastasis status using BSI and 2D-TBU extracted from VSBONE BSI for radium-223 treatment decisions.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>38517659</pmid><doi>10.1007/s12149-024-01918-4</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-2321-2984</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-7187 |
| ispartof | Annals of nuclear medicine, 2024-06, Vol.38 (6), p.450-459 |
| issn | 0914-7187 1864-6433 1864-6433 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2974009010 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Bone cancer Castration Evaluation Imaging Medicine Medicine & Public Health Metastases Metastasis Nuclear Medicine Original Article Prostate cancer Radioisotopes Radiology Radium Scintigraphy Survival Survival analysis Two dimensional analysis |
| title | Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A29%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20two-dimensional%20total%20bone%20uptake%20(2D-TBU)%20and%20bone%20scan%20index%20(BSI)%20extracted%20from%20active%20bone%20metastatic%20burden%20on%20the%20bone%20scintigraphy%20in%20patients%20with%20radium-223%20treatment&rft.jtitle=Annals%20of%20nuclear%20medicine&rft.au=Fukai,%20Shohei&rft.date=2024-06-01&rft.volume=38&rft.issue=6&rft.spage=450&rft.epage=459&rft.pages=450-459&rft.issn=0914-7187&rft.eissn=1864-6433&rft_id=info:doi/10.1007/s12149-024-01918-4&rft_dat=%3Cproquest_cross%3E3057773850%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3057773850&rft_id=info:pmid/38517659&rfr_iscdi=true |